Patents by Inventor Naoto Kusunose

Naoto Kusunose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WT1 substitution peptides
    Patent number: 7378384
    Abstract: Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: May 27, 2008
    Assignees: International Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu, Fumio Samizo, Naoto Kusunose, Masashi Nakatsuka
  • Wt1 substitution pepides
    Publication number: 20060205667
    Abstract: Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X—Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.
    Type: Application
    Filed: September 19, 2003
    Publication date: September 14, 2006
    Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu, Fumio Samizo, Naoto Kusunose, Masashi Nakatsuka
  • Peg-modified HGF
    Patent number: 5977310
    Abstract: This invention relates to a PEG-modified HGF (Hepatocyte Growth Factor), namely HGF modified by polyethylene glycol. The PEG-modified HGF of the invention has a prolonged clearance in vivo, effectively exhibits its physiological activity for a long period of time, and has the same physiological activity as HGF, which makes it possible to reduce the dose and relieve the side effects of the same.
    Type: Grant
    Filed: November 4, 1997
    Date of Patent: November 2, 1999
    Assignee: Toshikazu Nakamura and Sumitomo Pharmaceuticals Co., Ltd.
    Inventors: Mitsuo Namiki, Naoto Kusunose, Noriko Akimaru